Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 7/20 | 0.33 |
| ▸ | CTSK | P43235 | 5/20 | 0.33 |
| ▸ | CTSL | P07711 | 3/20 | 0.33 |
| ▸ | CTSH | P09668 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25309449 | 0.72 | TRPA1 (0.35) | TAAR1SIGMAR1 | |
| SCHEMBL1071752 | 0.72 | TRPA1 (0.35) | TAAR1SIGMAR1 | |
| SCHEMBL6642411 | 0.71 | SIGMAR1 (0.44) | SIGMAR1 | |
| SCHEMBL4820796 | 0.70 | — | — | |
| SCHEMBL128086 | 0.69 | TAAR1 (0.35) | TAAR1SIGMAR1 | |
| SCHEMBL3776672 | 0.69 | EPHX1 (0.32) | TAAR1SIGMAR1 | |
| SCHEMBL9330630 | 0.68 | TAAR1 (0.34) | TAAR1SIGMAR1 | |
| SCHEMBL27932397 | 0.68 | TAAR1 (0.34) | TAAR1SIGMAR1 | |
| SCHEMBL12873856 | 0.67 | ACE (0.56) | ACEMEN1KMT2ATAAR1CTSB | |
| SCHEMBL10044549 | 0.67 | ACE (0.56) | ACEMEN1KMT2ATAAR1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442698-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-10-28 | — | — | US | claimed |
| US-20050026914-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-02-03 | — | — | US | claimed |
| US-7442698-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20050026914-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026914-A1 | Substituted heterocyclic compounds and methods of use | NFATC1, ICOS, BET1 | ACE 2513/4885MEN1 120/4885KMT2A 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.